Guggenheim lowered the firm’s price target on Exact Sciences to $73 from $90 and keeps a Buy rating on the shares. The firm is applying a peer group median multiple on its 2025 revenue estimate given Shield could be FDA-approved with a broader label and the revenue ramp is slower than the firm anticipated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Refines Teams, Projects Growth Amid Leadership Changes
- Illumina appoints Cunningham as Chief Commercial Officer
- Exact Sciences assumed with a Buy at Jefferies
- Craig-Hallum would be buyers of Exact Sciences amid weakness
- Exact Sciences to present new data on screening and diagnostic portfolio at ASCO
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue